Skip to main content
NewslettersWatchlist

Resverlogix Corp(RVX-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.0550
Day High0.0600
Open:0.0600
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
AI-generated - The Globe and Mail
Resverlogix: Top 10 Undervalued Biotechnology Industry Stocks (RVX)
Newsfile
Resverlogix Announces Change to Its Board of Directors
Newsfile
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
AI-generated - The Globe and Mail
Resverlogix: Top 10 Undervalued Biotechnology Industry Stocks (RVX)
AI-generated - The Globe and Mail
Resverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)
Baystreet
Stocks in play: Resverlogix Corp.
Newsfile
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
Newsfile
Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
The Globe and Mail
Resverlogix: Top 10 Undervalued Biotechnology Industry Stocks (RVX)
Newsfile
Resverlogix Announces Warrant Repricing and One-Year Extension
Newsfile
Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders
Newsfile
Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
The Globe and Mail
Resverlogix: Top 10 Undervalued Biotechnology Industry Stocks (RVX)
The Globe and Mail
Resverlogix: Top 10 Undervalued Biotechnology Industry Stocks (RVX)
Newsfile
Resverlogix Announces One-Year Extension of Debenture
The Globe and Mail
Resverlogix: Top 10 Undervalued Nano Cap Stocks on TSX (RVX)
The Globe and Mail
Resverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)
The Globe and Mail
Resverlogix: Top 25 Undervalued Toronto Stock Exchange Stocks (RVX)
The Globe and Mail
Resverlogix: Top 10 Undervalued Nano Cap Stocks on TSX (RVX)
Newsfile
Resverlogix Announces New Research Highlighting Apabetalone's Potential Benefits in Cardiovascular Disease, Heart Failure, and COVID-19
The Globe and Mail
Resverlogix: Top 10 Undervalued Biotechnology Industry Stocks (RVX)
The Globe and Mail
Resverlogix: Top 10 Undervalued Biotechnology Industry Stocks (RVX)
The Globe and Mail
Resverlogix: Top 10 Undervalued Biotechnology Industry Stocks on TSE (RVX)
Globe Newswire
Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders
Baystreet
Stocks in play: Resverlogix Corp.
Globe Newswire
Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors
Globe Newswire
Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study
Globe Newswire
Resverlogix Announces One-Year Extension of Debenture
Globe Newswire
Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
AccessWire
The Power Play by The Market Herald Releases Interviews With Else Nutrition, Ayurcann Holdings, and Resverlogix
Globe Newswire
Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada
Globe Newswire
Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment

Profile

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.